Cover Image
市場調查報告書

全球流感市場

The Global Influenza Market

出版商 BCC Research 商品編碼 99390
出版日期 內容資訊 英文 189 Pages
訂單完成後即時交付
價格
Back to Top
全球流感市場 The Global Influenza Market
出版日期: 2018年04月18日 內容資訊: 英文 189 Pages
簡介

全球流感市場,預計從2016年的54億美元,2021年擴大到64億美元。預計市場2016年∼2021年以3.6%的年複合成長率成長。

本報告提供全球流感市場相關調查分析,市場概要,市場趨勢與預測,產品資訊,政府的配合措施,市場動態,主要企業簡介等系統性資訊。

第1章 簡介

第2章 摘要

第3章 產業概要

  • 定義
  • 市場歷史
    • 傳染病/大流行病
    • 病毒的變異
    • 流感的種類
    • 流感病毒的全球活動
  • WHO (世界衛生組織) 和CDC (疾病對策預防中心) :對流感的反應
  • 美國的病毒的監視
  • FDA的與疫苗關聯的生物製藥
  • 推薦疫苗
  • 月齡
  • 疫苗的有效性
  • 人口統計和流感的發病/死亡率
  • 流感造成的死亡

第4章 影響市場的問題點

  • H1N1大流行 (豬流感)
  • 國際的流感疫苗的儲存
  • 抗病毒抗性
  • 再生病毒
  • 宣傳媒體報道和疫苗接種
  • 流行/大流行病的威脅
  • 對大流行病的準備計劃
  • 紅外線感測器與熱探測相機
  • 美國
  • 日本
  • 中國
  • 巴西
  • 英國
  • 全球流感的影響

第5章 專利分析

  • 概要
  • 流感專利:各專利號碼
  • EMORY UNIVERSITY
  • GLAXOSMITHKLINE BIOLOGICALS SA
  • LONGHORN VACCINES AND DIAGNOSTICS LLC
  • NOVARTIS
  • NOVAVAX
  • 鹽野義製藥
  • ST. JUDE CHILDREN'S RESEARCH HOSPITAL
  • U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
  • UNIVERSITY OF PENNSYLVANIA
  • VERTEX PHARMACEUTICALS INC.
  • WISCONSIN ALUMNI RESEARCH FOUNDATION

第6章 流感疫苗

  • 概要
  • 目前疫苗
  • 疫苗開發

第7章 流感治療

  • 概要
  • 目前治療
  • 流感治療的發展
  • 全球流感治療市場
  • 各地區市場的摘要
  • 競爭企業分析

第8章 流感診斷

  • 概要
  • 檢驗內容
  • 產品說明
  • 實驗室服務
  • 各地區市場的摘要
  • 競爭企業分析

第9章 流感市場摘要

  • 流感市場趨勢概要
  • 綜合市場分析
  • 各地區市場的摘要

第10章 企業簡介

  • 重要的企業收購
  • ALERE INC.
  • ASTRAZENECA/MEDIMMUNE
  • BECTON DICKINSON AND COMPANY
  • CEPHEID
  • 第一三共
  • GLAXOSMITHKLINE PLC
  • HOLOGIC INC.
  • 田邊三菱製藥
  • MYLAN N.V.
  • ORASURE TECHNOLOGIES
  • PROTEIN SCIENCES CORPORATION
  • QIAGEN N.V.
  • QUIDEL CORP.
  • ROCHE LTD.
  • SANOFI/SANOFI PASTEUR
  • SEKISUI DIAGNOSTICS LLC
  • SEQIRUS CSL LIMITED

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHM049E

Report Highlights

The global influenza market totaled $5.6 million in 2017 and is estimated to reach $6.4 million by 2022, growing at a compound annual growth rate (CAGR) of 3.0% for the period of 2017-2022.

Report Includes:

  • 25 data tables and 77 additional tables
  • An overview of the global influenza market
  • Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Identification of segments with high growth potential and their future applications
  • Explanation of major drivers and regional dynamics of the market and current trends within the industry
  • Detailed profiles of major vendors in the market, including Alere Inc., MedImmune, LLC, Cepheid Inc., GlaxoSmithKline plc and Qiagen N.V.

Report Scope

This BCC Research report is designed to be a helpful business tool that provides a thorough evaluation of the market for influenza vaccines, therapeutics and diagnostics. The geographic scope of this study is global, with emphasis on U.S. and European data. The report identifies markets in general segments: Vaccines, Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, uses of products, forecasts and competitive analyses. Additionally, the study covers some of the most significant issues, trends and market factors.

Analyst Credentials

MELISSA ELDER is a healthcare market analyst specializing in treatments, medical equipment and devices. As a research analyst for more than 20 years, she also worked in medical training and advanced medical technologies. She holds a B.S. degree in business management and is pursuing an MBA in health care management from California Coast University.

Table of Contents

Chapter 1: Introduction

  • Influenza Overview
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

  • The Influenza Market: Summary of Major Markets

Chapter 3: Industry Overview and Background

  • Overview
  • History of the Market
    • Epidemics and Pandemics in History
    • Virus Mutations
    • Influenza Types
  • WHO and CDC Influenza Response
    • World Health Organization
    • Centers for Disease Control and Prevention
    • U.S. Viral Surveillance
    • FDA's Vaccine and Related Biological Products Advisory Committee and Vaccine Composition
  • Vaccine Recommendations
  • Vaccine Effectiveness
  • Universal Vaccine
  • Population Demographics and Influenza Incidence/Mortality
    • Global Demographics
    • Global Life Expectancy
  • Influenza Incidence and Mortality
    • The 2017-2018 Influenza Season (Through January 2018)

Chapter 4: Global Influenza Vaccine Market

  • Overview
    • Current Vaccines
  • The Global Influenza Vaccine Market
  • Seasonal versus Pandemic Sales
  • Regional Market Summary
  • The U.S. Influenza Vaccine Market
    • History of Vaccine Manufacturer Participation in the United States
  • The European Influenza Vaccine Market
  • Global Competitor Analysis
  • Influenza Vaccine Developments
    • Clinical Trials

Chapter 5: Global Influenza Therapeutics Market

  • Overview
    • Current Therapies
    • Generic Availability
  • The Global Influenza Therapeutics Market
  • Seasonal versus Pandemic Sales
  • Regional Market Summary
  • The U.S. Influenza Therapeutics Market
  • The European Influenza Therapeutics Market
  • Global Competitor Analysis
  • Influenza Treatment Developments
    • Clinical Trials

Chapter 6: Global Influenza Diagnostic Market

  • Overview
    • Test Descriptions
    • Product Descriptions
    • Laboratory Services
  • The Global Influenza Diagnostic Market
  • Regional Market Summary
  • Global Competitor Analysis

Chapter 7: Influenza Pandemic Impact

  • Epidemic/Pandemic Threat
  • H1N1 Outbreak 2009 (Swine Flu)
  • Rapid Diagnostics
    • Pandemic Testing
    • Seasonal Influenza Tests
  • Avian Flu
    • Avian Flu Surveillance
    • The WHO and Containment for Pandemic Influenza
  • International Influenza Vaccine Stockpile Orders
  • Pre-Pandemic Vaccination
    • Biomedical Advanced Research and Development Authority (BARDA)
  • Antiviral Resistance
  • Recreated Viruses
  • Immaterialized Market Risk
  • Media Coverage and Vaccinations
  • Pandemic Preparedness Plans
  • Infrared Sensors and Thermal Imagers
  • The United States
  • Japan
  • China
  • Brazil
  • United Kingdom

Chapter 8: Patent Review/New Developments

  • Overview
  • Influenza Patent Review by Country
  • Influenza Patent Review by Assignee
    • Massachusetts Institute of Technology (MIT)
    • Seqirus U.K. Limited
    • Academia Sinica
    • Celltrion Inc.
    • Icahn School of Medicine at Mount Sinai
    • Shionogi & Co. Ltd
    • Vertex Pharmaceuticals Inc.
    • Xiamen University

Chapter 9: Analysis of Market Opportunities

  • Overview of Influenza Market Trends
  • Total Market Analysis
    • Regional Market Summary

Chapter 10: Company Profiles

  • Significant Company Acquisitions

Appendix

  • Manufacturers and Developers
  • Approved WHO Influenza Centers
  • List of Acronyms
  • Glossary of Terms

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Table A Report Sources
  • Summary Table Global Influenza Market, by Product Type, Through 2022 ($ Millions)
    • Table 1: Distribution of Fatal Cases of H1N1 Pandemic, by WHO Region, 2009-2010 (%)
    • Table 2: CDC Estimates of 2009 H1N1 Cases and Related Hospitalizations and Deaths, by Age Group, April 2009-March 13, 2010
    • Table 3: Cumulative Number of Confirmed Cases of H7N9, by Region, 2013 to October 2016
    • Table 4: Viral Surveillance Share, by Flu Seasons and Influenza Virus Type, 2005-2018 (%)
    • Table 5: Influenza Virus Recommendations for U.S. Influenza Seasons, 2003-2018
    • Table 6: Thimerosal Content of Influenza Vaccines (U.S. Manufactured)
    • Table 7: CDC Influenza Vaccine Recommendations
    • Table 8: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2005-2017
    • Table 9: Global Population, by Selected Age Group, 2010-2050 (Millions)
    • Table 10: Global Population Average Growth Rate, by Broad Age Group, 2010-2050 (%)
    • Table 11: Global Population, by Selected Country, Through 2020 (Millions)
    • Table 12: Global Life Expectancy at Birth, by Selected Country, 1980-2020 (Years)
    • Table 13: U.S. Impact of 2009 H1N1 Influenza, Cases and Related Hospitalizations and Deaths, by Age Group, April 2009-2010
    • Table 14: U.S. Influenza Reporting Data Cumulative, Since October 1, 2017 (Week 40) to January 13, 2018 (Week 2)
    • Table 15: Examples of Marketed Seasonal Influenza Vaccine Products
    • Table 16: FDA Seasonal Influenza Vaccine Approvals, Based on Adult Dosage, 2017-2018
    • Table 17: Examples of Approved Pandemic Influenza Vaccine Products
    • Table 18: Global Market for Influenza Vaccines, by Manufacturer, Through 2022 ($ Millions)
    • Table 19: Global Market for Influenza Vaccines, by Country, 2017 ($ Millions/%)
    • Table 20: Global Market for Influenza Vaccines, by Region, Through 2022 ($ Millions)
    • Table 21: U.S. Market for Influenza Vaccines, by Manufacturer, Through 2022 ($ Millions)
    • Table 22: Influenza Vaccine Manufacturer Participation in the U.S., 2004-2018
    • Table 23: European Market for Influenza Vaccines, by Manufacturer, Through 2022 ($ Millions)
    • Table 24: European Market for Influenza Vaccines, by Country, 2017 ($ Millions/%)
    • Table 25: Global Competitor Market Analysis for Influenza Vaccines, 2017 ($ Millions/%)
    • Table 26: Clinical Trials for Influenza Prevention (Vaccines and Biologics), by Selected Country and Trial Status
    • Table 27: Altimmune Influenza Vaccine Pipeline
    • Table 28: BIKEN Influenza Vaccine Pipeline
    • Table 29: BiondVax Pharmaceuticals Influenza Vaccine Pipeline
    • Table 30: Changchun BCHT Biotechnology Influenza Vaccine Pipeline
    • Table 31: Eurocine Vaccines Influenza Vaccine Pipeline
    • Table 32: FluGen Influenza Vaccine Pipeline
    • Table 33: Folia Biotech Vaccines Influenza Vaccine Pipeline
    • Table 34: Green Cross Corp. Influenza Vaccine Pipeline
    • Table 35: Institute of Vaccines and Medical Biologicals, Vietnam Influenza Vaccine Pipeline
    • Table 36: Medicago Influenza Vaccine Pipeline
    • Table 37: MedImmune Influenza Vaccine Pipeline
    • Table 38: Mitsubishi Tanabe Influenza Vaccine Pipeline
    • Table 39: Moderna Therapeutics Influenza Vaccine Pipeline
    • Table 40: NanoBio Corp. Influenza Vaccine Pipeline
    • Table 41: Nitto Denko Influenza Vaccine Pipeline
    • Table 42: Novavax Influenza Vaccine Pipeline
    • Table 43: Pantec Biosolutions Influenza Vaccine Pipeline
    • Table 44: Sanofi Pasteur Influenza Vaccine Pipeline
    • Table 45: Seqirus Influenza Vaccine Pipeline
    • Table 46: Vaccitech Influenza Vaccine Pipeline
    • Table 47: Vaxart Influenza Vaccine Pipeline
    • Table 48: Marketed Influenza Therapies, by Manufacturer, 2017
    • Table 49: Generic FDA Approvals for Influenza Therapies
    • Table 50: Global Market for Influenza Therapeutics, by Manufacturer, Through 2022 ($ Millions)
    • Table 51: Global Market for Influenza Therapeutics, by Region, Through 2022 ($ Millions)
    • Table 52: U.S. Market for Influenza Therapeutics, by Manufacturer, Through 2022 ($ Millions)
    • Table 53: European Market for Influenza Therapeutics, by Manufacturer, Through 2022 ($ Millions)
    • Table 54: Global Competitor Market Analysis for Influenza Therapeutics, 2017 ($ Millions/%)
    • Table 55: Clinical Trials for Influenza Therapeutics by Selected Country and Trial Status
    • Table 56: Amarillo Biosciences Influenza Treatment Pipeline
    • Table 57: Ansun BioPharma Influenza Treatment Pipeline
    • Table 58: AstraZeneca Influenza Treatment Pipeline
    • Table 59: Daiichi Sankyo Influenza Treatment Pipeline
    • Table 60: Emergent BioSolutions Influenza Treatment Pipeline
    • Table 61: GlaxoSmithKline Influenza Treatment Pipeline
    • Table 62: Hemispherx Biopharma Influenza Treatment Pipeline
    • Table 63: Il-Yang Influenza Treatment Pipeline
    • Table 64: Janssen Pharmaceutical Co. Influenza Treatment Pipeline
    • Table 65: NanoViricides Influenza Vaccine Pipeline
    • Table 66: Sarepta Therapeutics Influenza Treatment Pipeline
    • Table 67: Shionogi Influenza Treatment Pipeline
    • Table 68: Toyama Chemical Influenza Treatment Pipeline
    • Table 69: Visterra Influenza Treatment Pipeline
    • Table 70: Influenza Diagnostic Table
    • Table 71: Clinical Considerations of Rapid Testing During High Influenza Prevalence
    • Table 72: Clinical Considerations of Rapid Testing During Low Influenza Prevalence
    • Table 73: Selected Marketed Influenza Products, January 2018
    • Table 74: Selected Rapid Influenza Tests Average Price ($)
    • Table 75: Global Providers of Test Services
    • Table 76: Global Market for Influenza Diagnostics, by Product Classification, Through 2022 ($ Millions)
    • Table 77: Global Market for Influenza Diagnostics, by Region, Through 2022 ($ Millions)
    • Table 78: CLIA-waived Approvals for Influenza Indications in the U.S., 2000-2017
    • Table 79: Global Competitor Market Analysis for Influenza Diagnostics, by Manufacturer, 2017 ($ Millions/%)
    • Table 80: Estimated Incidence of Pandemic Influenza, Severe Outbreaks Based on 2017- Population, U.S. Census Bureau International Database, Selected Countries (Thousands)
    • Table 81: Countries Affected by Current CDC and USDA Bird Import Restrictions
    • Table 82: Countries with Temporary Restrictions on Importation of Avian Commodities, CDC and USDA Restrictions
    • Table 83: WHO-Reported Cases of Avian Influenza A/(H5N1) in Humans, 2003-2017
    • Table 84: Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2017
    • Table 85: Essential and Desirable Elements of the WHO Influenza Pandemic Preparedness Plan
    • Table 86: Japan's Action Plan for Influenza Pandemic Preparedness
    • Table 87: China Influenza Pandemic Warning Levels
    • Table 88: Brazil Influenza Pandemic Warning Levels and Action
    • Table 89: Patents for Influenza, by Year Issued, 2002-2017
    • Table 90: Recent Patents for Influenza Technology, by Patent Number
    • Table 91: Recent Patents for Influenza Technology, by Country
    • Table 92: Number of U.S. Patents, by Influenza Market Competitor
    • Table 93: Influenza Vaccine Market, by Drivers and Challenges
    • Table 94: Influenza Therapeutic Market, by Drivers and Challenges
    • Table 95: Influenza Diagnostic Market, by Drivers and Challenges
    • Table 96: Global Influenza Market, by Product Segment, Through 2022 ($ Millions)
    • Table 97: Global Influenza Market, by Region, Through 2022 ($ Millions)
    • Table 98: U.S. Influenza Market, by Segment, Through 2022 ($ Millions)
    • Table 99: European Influenza Market, by Segment, Through 2022 ($ Millions)
    • Table 100: Approved WHO Influenza Centers, by Region
    • Table 101: Abbreviations Used in Influenza Markets
    • Table 102: Glossary of Terms Used in Influenza Markets

List of Figures

  • Summary Figure Global Influenza Market, by Product Type, 2016-2022 ($ Millions)
    • Figure 1: Viral Surveillance Share, by flu seasons and Influenza Virus Type, 2005-2018 (%)
    • Figure 2: Recommendations Regarding Influenza Vaccination of Persons Allergic to Eggs: Advisory Committee on Immunization Practices for U.S. Influenza Season, 2017-2018
    • Figure 3: Global Population, by Selected Age Group, 2010-2050 (Millions)
    • Figure 4: Global Population Average Growth Rate, by Broad Age Group, 2010-2050 (%)
    • Figure 5: Global Population, by Selected Country, 2010-2020 (Millions)
    • Figure 6: Global Life Expectancy at Birth, by Selected Country, 1980-2020 (Years)
    • Figure 7: Weekly Influenza Surveillance Report, 2017-2018 (Week 2, Ending January 13, 2018)
    • Figure 8: Global Market for Influenza Vaccines, by Manufacturer, 2016-2022 ($ Millions)
    • Figure 9: Global Market for Influenza Vaccines, by Country, 2017 ($ Millions/%)
    • Figure 10: Global Market Share of Influenza Vaccine Sales, by Country, 2017 (%)
    • Figure 11: Global Market for Influenza Vaccines, by Vaccine Type, 2007-2017 ($ Millions)
    • Figure 12: Global Market for Influenza Vaccines, by Region, 2016-2022 ($ Millions)
    • Figure 13: Global Market Share of Influenza Vaccine, by Region, 2017 (%)
    • Figure 14: U.S. Market for Influenza Vaccines, by Manufacturer, 2016-2022 ($ Millions)
    • Figure 15: U.S. Market Share of Influenza Vaccine, by Manufacturer, 2017 (%)
    • Figure 16: U.S. Lot Share of Influenza Vaccine by Manufacturer, 2017-2018 (%)
    • Figure 17: European Market for Influenza Vaccines, by Manufacturer, 2016-2022 ($ Millions)
    • Figure 18: European Market Share of Influenza Vaccine, by Manufacturer, 2017 (%)
    • Figure 19: European Market for Influenza Vaccines, by Country, 2017 ($ Millions/%)
    • Figure 20: European Market Share of Influenza Vaccine, by Country, 2017 (%)
    • Figure 21: Global Competitor Market Analysis for Influenza Vaccines, 2017 ($ Millions)
    • Figure 22: Global Market Share of Influenza Vaccine, by Manufacturer, 2017 (%)
    • Figure 23: Global Market for Influenza Therapeutics, by Manufacturer, 2016-2022 ($ Millions)
    • Figure 24: Global Market for Influenza Therapeutics, by Contract Type, 2007-2017 ($ Millions)
    • Figure 25: Global Market for Influenza Therapeutics, by Region, 2016-2022 ($ Millions)
    • Figure 26: Global Market Share of Influenza Therapeutics, by Region, 2017 (%)
    • Figure 27: U.S. Market for Influenza Therapeutics, by Manufacturer, 2016-2022 ($ Millions)
    • Figure 28: U.S. Market Share of Influenza Therapeutics, by Manufacturer, 2017 (%)
    • Figure 29: European Market for Influenza Therapeutics, by Manufacturer, 2016-2022 ($ Millions)
    • Figure 30: European Market Share of Influenza Therapeutic, by Manufacturer, 2017 (%)
    • Figure 31: Global Competitor Market Analysis for Influenza Therapeutics, 2017 ($ Millions)
    • Figure 32: Global Market Share of Influenza Therapeutic Sales, by Manufacturer, 2017 (%)
    • Figure 33: Global Market for Influenza Diagnostics, by Product Classification, 2016-2022 ($ Millions)
    • Figure 34: Global Market Share of Influenza Diagnostics, by Product Classification, 2017 (%)
    • Figure 35: Global Market Share of Conventional Laboratory Influenza Diagnostic, by Product Type, 2017 (%)
    • Figure 36: Global Market Share of Rapid Influenza Diagnostic, by Product Type, 2017 (%)
    • Figure 37: Global Market for Influenza Diagnostics, by Region, 2016-2022 ($ Millions)
    • Figure 38: Global Market Share of Influenza Diagnostics, by Region, 2017 (%)
    • Figure 39: CLIA-waived Approvals for Influenza Indications in the U.S., 2000-2017
    • Figure 40: Global Competitor Market Analysis for Influenza Diagnostics, 2017 ($ Millions)
    • Figure 41: Global Market Share of Influenza Diagnostic, by Manufacturer, 2017 (%)
    • Figure 42: WHO-Reported Cases of Avian Influenza A/(H5N1) in Humans, 2003-2017 (No.)
    • Figure 43: Number of Approved WHO Influenza Centers, by WHO Broad Region
    • Figure 44: Targeted Pre-Pandemic Influenza Vaccine Stockpiles, Based on Population Demands for Selected Countries (Millions)
    • Figure 45: Patents for Influenza, by Year Issued, 2002-2017 (No. of Patents)
    • Figure 46: Recent Patents for Influenza Technology, by Country (No. of patents)
    • Figure 47: Global Influenza Market, by Product Segment, 2016-2022 ($ Millions)
    • Figure 48: Global Influenza Market Share, by Product Segment, 2017 (%)
    • Figure 49: Global Influenza Market, by Region, 2016-2022 ($ Millions)
    • Figure 50: Global Influenza Market Share, by Region, 2017 (%)
    • Figure 51: U.S. Influenza Market, by Segment, 2016-2022 ($ Millions)
    • Figure 52: U.S. Influenza Market Share, by Segment, 2017 (%)
    • Figure 53: European Influenza Market, by Segment, 2016-2022 ($ Millions)
    • Figure 54: European Influenza Market Share, by Segment, 2017 (%)
Back to Top